Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bertilimumab Cambridge Antibody Technology Group.

Changhai Ding1, Jun Li, Xuejue Zhang

  • 1Menzies Research Institute, University of Tasmania, Hobart 7000, Tasmania, Australia. changhai.ding@utas.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|December 3, 2004
PubMed
Summary

Cambridge Antibody Technology is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for allergic disorders. Phase I/II trial results were released by September 2003, with licensing opportunities sought.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in heterogeneity and classification of osteoarthritis.

Bone research·2026
Same author

Bidirectional Relationship and Shared Mechanisms Between Sarcopenia and Osteoporosis: An Observational Study Integrating Genomic, Proteomic, and Metabolomic Data.

Aging cell·2026
Same author

Tristetraprolin protects against osteoarthritis by restraining chondrocyte mitochondrial DNA release through post-transcriptional regulation.

Journal of orthopaedic translation·2026
Same author

Temporal Trends and Cross-Country Inequalities in the Burden of Osteoarthritis, 1990-2021: Findings From the Global Burden of Disease Study 2021.

International journal of rheumatic diseases·2026
Same author

Corrigendum to 'Vitamins D and K jointly protect against osteoarthritis via regulating OSCAR during osteoclastogenesis' [J Orthop Transl <b>52</b> (2025) 387-403].

Journal of orthopaedic translation·2026
Same author

Associations of centrally acting analgesic use with total joint arthroplasty compared to selective serotonin reuptake inhibitor among osteoarthritis patients in a large prospective cohort.

BMC medicine·2026

Area of Science:

  • Immunology and Allergy Research
  • Monoclonal Antibody Development
  • Pharmacology

Background:

  • Allergic disorders represent a significant global health burden.
  • Eotaxin-1 is a chemokine implicated in allergic inflammation.
  • Targeting eotaxin-1 offers a potential therapeutic strategy for allergic diseases.

Purpose of the Study:

  • To evaluate the safety and efficacy of bertilimumab, an anti-eotaxin-1 monoclonal antibody.
  • To assess the potential of bertilimumab in treating allergic disorders.
  • To present interim results from Phase I/II clinical trials.

Main Methods:

  • Development of bertilimumab, a human IgG1 monoclonal antibody targeting eotaxin-1.
  • Phase I/II clinical trials to assess safety, tolerability, and preliminary efficacy.

Related Experiment Videos

  • Pharmacokinetic and pharmacodynamic assessments.

    • Main Results:

    • Phase I/II trials for bertilimumab have been completed.
    • Results from these trials were available by September 2003.
    • The study focused on the potential therapeutic application in allergic conditions.

    Conclusions:

    • Bertilimumab demonstrates potential as a treatment for allergic disorders.
    • Further development and outlicensing are being pursued.
    • Targeting eotaxin-1 is a viable approach in managing allergic diseases.